Parallel Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Parallel Advisors, LLC

$3.87 Billion
Q2 2024

A detailed history of Parallel Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 6,372 shares of VRTX stock, worth $3.29 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

6,372

Previous 5,509 15.67%

Holding current value

$3.29 Million

Previous $2.3 Million 29.71%

% of portfolio

0.08%

Previous 0.06%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$392.81 - $485.53 $338,995 - $419,012	863 Added 15.67%	6,372 $2.99 Million
Q1 2024 May 06, 2024	BUY	$407.69 - $446.08 $298,836 - $326,976	733 Added 15.35%	5,509 $2.3 Million
Q4 2023 Feb 09, 2024	BUY	$343.0 - $410.68 $448,987 - $537,580	1,309 Added 37.76%	4,776 $1.94 Million
Q3 2023 May 20, 2024	BUY	$338.18 - $362.46 $81,839 - $87,715	242 Added 7.5%	3,467 $1.21 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $81,839 - $87,715	242 Added 7.5%	3,467 $1.21 Million
Q2 2023 May 20, 2024	BUY	$314.42 - $351.91 $55,652 - $62,288	177 Added 5.81%	3,225 $1.13 Million
Q2 2023 Aug 04, 2023	BUY	$314.42 - $351.91 $55,652 - $62,288	177 Added 5.81%	3,225 $1.13 Million
Q1 2023 May 20, 2024	SELL	$283.23 - $323.1 $697,029 - $795,149	-2,461 Reduced 44.67%	3,048 $960,000
Q1 2023 Apr 25, 2023	BUY	$283.23 - $323.1 $238,762 - $272,373	843 Added 38.23%	3,048 $960,000
Q4 2022 Feb 03, 2023	BUY	$285.76 - $321.48 $6,286 - $7,072	22 Added 1.01%	2,205 $636,000
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $43,538 - $48,579	159 Added 7.86%	2,183 $632,000
Q2 2022 Aug 01, 2022	BUY	$234.96 - $292.55 $16,682 - $20,771	71 Added 3.64%	2,024 $570,000
Q1 2022 Apr 28, 2022	BUY	$221.42 - $260.97 $22,363 - $26,357	101 Added 5.45%	1,953 $501,000
Q4 2021 Jan 20, 2022	BUY	$177.01 - $223.45 $70,804 - $89,380	400 Added 27.55%	1,852 $407,000
Q3 2021 Nov 02, 2021	BUY	$181.39 - $202.99 $20,859 - $23,343	115 Added 8.6%	1,452 $263,000
Q2 2021 Aug 06, 2021	BUY	$187.49 - $221.1 $12,936 - $15,255	69 Added 5.44%	1,337 $270,000
Q1 2021 Apr 23, 2021	BUY	$207.02 - $241.31 $4,554 - $5,308	22 Added 1.77%	1,268 $272,000
Q4 2020 Feb 02, 2021	SELL	$207.01 - $276.09 $27,118 - $36,167	-131 Reduced 9.51%	1,246 $294,000
Q3 2020 Oct 27, 2020	SELL	$255.65 - $303.1 $14,060 - $16,670	-55 Reduced 3.84%	1,377 $375,000
Q2 2020 Jul 16, 2020	BUY	$225.48 - $295.8 $35,174 - $46,144	156 Added 12.23%	1,432 $415,000
Q1 2020 Apr 27, 2020	BUY	$199.77 - $247.81 $29,765 - $36,923	149 Added 13.22%	1,276 $303,000
Q4 2019 Jan 30, 2020	BUY	$166.71 - $223.91 $8,002 - $10,747	48 Added 4.45%	1,127 $247,000
Q3 2019 Nov 01, 2019	BUY	$166.23 - $187.09 $23,770 - $26,753	143 Added 15.28%	1,079 $183,000
Q2 2019 Aug 05, 2019	SELL	$164.61 - $190.37 $10,370 - $11,993	-63 Reduced 6.31%	936 $172,000
Q1 2019 May 01, 2019	SELL	$163.73 - $194.7 $15,063 - $17,912	-92 Reduced 8.43%	999 $184,000
Q4 2018 Feb 05, 2019	BUY	$151.91 - $192.21 $9,114 - $11,532	60 Added 5.82%	1,091 $180,000
Q3 2018 Nov 01, 2018	BUY	$167.73 - $192.74 $1,677 - $1,927	10 Added 0.98%	1,031 $199,000
Q2 2018 Jul 30, 2018	BUY	$145.72 - $169.96 $25,938 - $30,252	178 Added 21.12%	1,021 $173,000
Q1 2018 May 08, 2018	BUY	$151.6 - $177.13 $4,396 - $5,136	29 Added 3.56%	843 $137,000
Q4 2017 Feb 13, 2018	SELL	$137.28 - $155.55 $2,196 - $2,488	-16 Reduced 1.93%	814 $122,000
Q3 2017 Nov 15, 2017	BUY	$148.13 - $162.24 $122,947 - $134,659	830 New	830 $123,000
Q3 2017 Nov 14, 2017	SELL	$148.13 - $162.24 $113,615 - $124,438	-767 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	767	767 $116,000

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Vertex Pharmaceuticals Inc Transaction History